BioStem Technologies Inc (OTCPK:BSEM)

Q3 2025 Biostem Technologies Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $4.14 (-10.97%)

Transcript

Key Points

Positve

BioStem Technologies Inc (BSEM) reported a 40% increase in product volume sold, indicating strong underlying demand despite a challenging pricing environment.
The company has achieved 7 consecutive quarters of positive adjusted EBITDA, showcasing the resilience and profitability of its business model.
BioStem Technologies Inc (BSEM) is preparing for a planned Nasdaq uplisting, which could enhance visibility and shareholder liquidity.
The company is expanding its market reach by entering new channels such as Medicaid and the Department of Veteran Affairs, which are significant growth opportunities.
BioStem Technologies Inc (BSEM) has a strong clinical foundation, with recent successful trials demonstrating the efficacy of its products in wound care.

Negative

Reported revenue decreased from $11 million in Q2 to $10.5 million in Q3, reflecting pricing pressures and competition.
The company had to restate its financials due to changes in accounting treatment for service fees, which may raise concerns about financial transparency.
Gross margin declined from 93.8% in the prior period to 88.5% in Q3, due to a shift towards products with licensing fees and lower selling prices.
The cash balance decreased from $30.8 million at the end of Q2 to $27.2 million at the end of Q3, partly due to land purchases and timing of collections.
The transition to a flat rate reimbursement model in 2026 poses a risk, as it may impact pricing strategies and revenue generation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BSEM.PK - Biostem Technologies Inc
Q3 2025 Biostem Technologies Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the BioStem Technologies 3rd quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session, and if you would like to ask a question during this time, please press 1 on your telephone keypad.

I would now like to turn the conference over to Tripp Taylor Investor Relations. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon everyone, and thank you for joining our conference call to discuss Biostem's 3rd quarter

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.